Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have been assigned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $79.8571.

Several research analysts recently issued reports on TARS shares. Mizuho began coverage on Tarsus Pharmaceuticals in a research report on Thursday, November 20th. They set an “outperform” rating and a $100.00 target price on the stock. HC Wainwright upped their price objective on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a “neutral” rating in a report on Monday, October 20th. Guggenheim lifted their target price on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Barclays initiated coverage on shares of Tarsus Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $100.00 price target for the company.

Tarsus Pharmaceuticals Price Performance

Shares of TARS opened at $68.15 on Wednesday. The company has a 50 day moving average of $78.32 and a two-hundred day moving average of $65.11. The company has a quick ratio of 4.25, a current ratio of 4.29 and a debt-to-equity ratio of 0.22. Tarsus Pharmaceuticals has a twelve month low of $38.51 and a twelve month high of $85.25. The company has a market cap of $2.89 billion, a price-to-earnings ratio of -33.74, a price-to-earnings-growth ratio of 0.98 and a beta of 0.59.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. The business had revenue of $118.70 million for the quarter, compared to the consensus estimate of $114.22 million. Tarsus Pharmaceuticals had a negative return on equity of 26.29% and a negative net margin of 22.17%. As a group, analysts predict that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the completion of the sale, the chief executive officer owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. The trade was a 0.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Dianne C. Whitfield sold 7,397 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total value of $592,499.70. Following the sale, the insider owned 38,958 shares in the company, valued at approximately $3,120,535.80. The trade was a 15.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 8.97% of the company’s stock.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Tarsus Pharmaceuticals by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock valued at $1,137,000 after acquiring an additional 1,217 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Tarsus Pharmaceuticals by 2.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock worth $3,659,000 after purchasing an additional 1,394 shares during the last quarter. Jane Street Group LLC lifted its position in Tarsus Pharmaceuticals by 105.8% during the first quarter. Jane Street Group LLC now owns 10,456 shares of the company’s stock valued at $537,000 after purchasing an additional 190,000 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Tarsus Pharmaceuticals by 26.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock valued at $66,000 after purchasing an additional 339 shares during the last quarter. Finally, KLP Kapitalforvaltning AS grew its position in Tarsus Pharmaceuticals by 27.8% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,900 shares of the company’s stock worth $280,000 after purchasing an additional 1,500 shares during the period. Institutional investors and hedge funds own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.